clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00009893 |
P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
P17 | country | United States of America | Q30 |
P582 | end time | 2005-01-01 | |
P4135 | maximum age | 120 | |
P1050 | medical condition | cholangiocarcinoma | Q124292 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 42 | |
P4844 | research intervention | fluorouracil | Q238512 |
calcium oxalate | Q412399 | ||
leucovorin calcium | Q27077063 | ||
P6153 | research site | Metro-Minnesota Community Oncology Research Consortium | Q30269543 |
Rapid City Regional Hospital | Q30280592 | ||
P580 | start time | 2001-05-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma |